References
- Coates A, Abraham S, Kaye S B, et al. On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203–8
- Cubeddu L X, Hoffmann I S, Fuenmayor N T, Finn A L. Efficacy of ondansetron (GR 380323) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322: 810–6
- Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816–21
- Sorbe B, Glimelius B, Hansen O, Högberg T H, Pruemm V. A multicenter, randomised study comparing the anti-emetic effects of the 5-HT3 antagonist ICS 205–930 with a metoclopramide-containing antiemetic cocktail in patients receiving cisplatin chemotherapy. Ann Oncol 1990; 113, (Suppl 1)
- Jones A L, Hill A S, Soukop M, et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991; 338: 483–7
- Bregni M, Siena S, Di Nicola M, Bonadonna G, Gianni A M. Granisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkyl ting agent cancer chemotherapy. Eur J Cancer 1991; 27: 561–5
- DeMulder H M, Seynaeve C, Vermorken J B, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834–40
- Smith D B, Newlands E S, Rustin G J, et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 1991; 338: 487–90